ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
The efficacy, safety, and outcomes of testosterone use among transgender men patients
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tareload" data-source="post: 238933"><p>[URL unfurl="true"]https://www.sciencedirect.com/science/article/pii/S0015028220307226[/URL]</p><p></p><h3>Subjects</h3><p>Our study population was composed of 157 TGM receiving medical attention at the Department of <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/endocrinology" target="_blank">Endocrinology</a> and Nutrition at the University Hospital Dr. Peset, Valencia, Spain. The following criteria were applied: having been assigned 12-week treatment with <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/testosterone" target="_blank">testosterone</a> undecanoate (intramuscular) at a dose of 1,000 mg; no treatment that could have interfered with the physiological function of the gonadal-pituitary-hypothalamic axis in the previous 6 months; no infectious, inflammatory, malignant, hematological, or organic disease; and absence of history of heart disease, stroke, <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/thromboembolism" target="_blank">thromboembolism</a>, <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/hyperlipidemia" target="_blank">hyperlipidemia</a>, hypertension, <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/polycystic-ovary-syndrome" target="_blank">PCOS</a>, or diabetes mellitus. Transgender men were evaluated and managed according to <em><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/diagnostic-and-statistical-manual-of-mental-disorders" target="_blank">Diagnostic and Statistical Manual of Mental Disorders</a> V</em> criteria. Eligibility of the subjects for gender-affirming hormone treatment was determined following the guidelines of the World Professional Association for Transgender Health and those of the Endocrine Society. All the subjects were naive to hormonal treatment and eugonadal, which were confirmed by medical history, physical examination, and biochemical criteria before initiating treatment. <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/ovariectomy" target="_blank">Oophorectomy</a> was not performed in any of these patients.All participants were informed about all the methods and procedures of the study and gave their written consent. The study was conducted in accordance with the Helsinki Declaration and approved by the Ethics Committee of University Hospital Dr. Peset (ID: 98/19).</p><p></p><h3>Conclusion</h3><p>Although gender-affirming hormones are considered medically necessary, the present research demonstrates that testosterone can induce an increase in leukocyte-endothelium interactions, adhesion molecules, and proinflammatory cytokines in TGM. Future research concerning endothelial impairment and inflammation may determine the physiological mechanism involved in this effect, an effect that should be taken into account to monitor cardiovascular risk in these individuals.</p></blockquote><p></p>
[QUOTE="tareload, post: 238933"] [URL unfurl="true"]https://www.sciencedirect.com/science/article/pii/S0015028220307226[/URL] [HEADING=2]Subjects[/HEADING] Our study population was composed of 157 TGM receiving medical attention at the Department of [URL='https://www.sciencedirect.com/topics/medicine-and-dentistry/endocrinology']Endocrinology[/URL] and Nutrition at the University Hospital Dr. Peset, Valencia, Spain. The following criteria were applied: having been assigned 12-week treatment with [URL='https://www.sciencedirect.com/topics/medicine-and-dentistry/testosterone']testosterone[/URL] undecanoate (intramuscular) at a dose of 1,000 mg; no treatment that could have interfered with the physiological function of the gonadal-pituitary-hypothalamic axis in the previous 6 months; no infectious, inflammatory, malignant, hematological, or organic disease; and absence of history of heart disease, stroke, [URL='https://www.sciencedirect.com/topics/medicine-and-dentistry/thromboembolism']thromboembolism[/URL], [URL='https://www.sciencedirect.com/topics/medicine-and-dentistry/hyperlipidemia']hyperlipidemia[/URL], hypertension, [URL='https://www.sciencedirect.com/topics/medicine-and-dentistry/polycystic-ovary-syndrome']PCOS[/URL], or diabetes mellitus. Transgender men were evaluated and managed according to [I][URL='https://www.sciencedirect.com/topics/medicine-and-dentistry/diagnostic-and-statistical-manual-of-mental-disorders']Diagnostic and Statistical Manual of Mental Disorders[/URL] V[/I] criteria. Eligibility of the subjects for gender-affirming hormone treatment was determined following the guidelines of the World Professional Association for Transgender Health and those of the Endocrine Society. All the subjects were naive to hormonal treatment and eugonadal, which were confirmed by medical history, physical examination, and biochemical criteria before initiating treatment. [URL='https://www.sciencedirect.com/topics/medicine-and-dentistry/ovariectomy']Oophorectomy[/URL] was not performed in any of these patients.All participants were informed about all the methods and procedures of the study and gave their written consent. The study was conducted in accordance with the Helsinki Declaration and approved by the Ethics Committee of University Hospital Dr. Peset (ID: 98/19). [HEADING=2]Conclusion[/HEADING] Although gender-affirming hormones are considered medically necessary, the present research demonstrates that testosterone can induce an increase in leukocyte-endothelium interactions, adhesion molecules, and proinflammatory cytokines in TGM. Future research concerning endothelial impairment and inflammation may determine the physiological mechanism involved in this effect, an effect that should be taken into account to monitor cardiovascular risk in these individuals. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
The efficacy, safety, and outcomes of testosterone use among transgender men patients
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top